29/04/2016. Biosimilars An NHS perspective. Aim. Maggie Dolan Regional Pharmacy Procurement Specialist South East Coast April 2016
|
|
- Pearl McKenzie
- 5 years ago
- Views:
Transcription
1 Biosimilars An NHS perspective Maggie Dolan Regional Pharmacy Procurement Specialist South East Coast April 2016 Aim The changing medicines landscape driving patient access to medicines the Biosimilar Medicine Challenges Ongoing considerations 2 1
2 Medicines are changing Value of generic medicines to the NHS Health Economy 12.2billion saved in That is the extra cost if all community pharmacy prescriptions had been fulfilled as branded products Generic medicine usage is 75.20% of all prescriptions in primary care Secondary care (hospital) spend on generics 250m /annum Contracting for generic medicines delivered a 30million cost saving to Trusts across England in 2014/2015 Branded to Generic maximum point of savings Automatic substitution to generics in secondary care 4 2
3 Generics - Supporting patients access to life changing medicines Generics at transition 70-90% price reduction Biosimilars - 40%? More competitive pricing / wider availability Cash releasing contracting allows :- investment in new and innovative medicines the NHS to treat more patients Learnings from the biologic therapies prior to 2015 a) EPO an established market with many brands, rapid price reductionquestionable opportunity for biosimilars b) GCSF market rapidly went generic as it was a product used short term (i.e. no switching of existing patients) with a direct measure of effectiveness. So biosimilar took over. (wholesale introduction based on price similar to generics) c) Growth Hormone. Brands have maintained product differentiation with device design and needleless systems This has prevented penetration of biosimilar. Very different adoption approaches across the NHS (no standardisation) No join up between policy, national and local strategies /duplication of effort 3
4 It s the loss of exclusivity that drives biosimilar interest All these products will lose patent protection in EU by 2020 Global Sales (MAT 06/2014), US$ billion Total ~ US$ 79 billion Adalimumab (Humira) Insulin Glargine (Lantus) Etanercept (Enbrel) Infliximab (Remicade) Rituximab (Mabthera) Pegfilgrastim (Neulasta) Ranibizumab (Lucentis) Insulin Aspart (Novomix, Novorapid) Bevacizumab (Avastin) Interferon Beta-1A (Avonex, Rebif) Trastuzumab (Herceptin) Glatiramer Acetate (Copaxone) EU expiry date US expiry date (extended) Expired 2018 Expired Expired Not considered existing biosimilars such as Epoetin Alfa expired in EU, but still patent protected in the US Source: IMS MIDAS, 06/2014, Rx bound, IMS Patent focus 7 Uptake of biosimilars across Europe 4
5 Pharmacey MSG Biosimilars Group Purpose To devise a strategy to ensure the NHS makes best use of Biosimilar whilst Tasks medicines which has patient safety as a priority supporting a robust Biosimilar market Membership 4 Nations NICE, CMU, Trusts, Commissioners CCGs, NHSE Specialist Pharmacy Services - Regional Procurement, QA, MI Assess Pipeline engage with suppliers Understand barriers to uptake / behaviour of the originators? Provide resources for NHS/ patient educational opportunities Support clinical engagement and contracting Collect data on uptake / implementation Pharmaceutical Industry Sector Board - Biosimilars NHS CoSolutions mmercial
6 Need for policy alignment NHS England Clinical and Scientific Policy and Strategy Group - Biosimilars Chaired by Chief Pharmacist (Dr Keith Ridge ) Membership includes MHRA ABPI BGMA NICE NHS providers NHS Commisioners Activities to date Biosimilars Q/A document (July 2015) National workshops (March 2016) to support development of a toolkit to support local uptake 12 6
7 Key messages agreed by partnership organisations Messages disseminated to NHS stakeholders On NHSE web almost 1000 downloads to date What is a Biosimilar Medicine? 13 Analysis of uptake Clinician buy in essential education support from clinical pharmacists Patient engagement critical share comms/ documentation across Trusts Protected time to switch patients Share the savings locally INVEST TO SAVE 14 7
8 At the end of 2015, there were some 41 biosimilar medicines in the pipeline for four key original biologics Biosimilars in the Pipeline (PRX-106) Protalix Biocon BioXpress Etanercept Harvest Moon Adalimumab Filed Late Phase Early Phase Preclinical BioXpress FKB327 (Kyowa Kirin) M923 (Momenta) ABP501 (Amgen) PF (Pfizer) BioXpress Oncobiologics Avasthagen Tunex (Mycenax ) LBEC0101(LG Life) CHS-0214 (Coherus) LBAL (LG Life) GP2015 (Sandoz) ABP 710 (Amgen) NI-071 (Nichiiko) BOW15 (Epirus) GP2017 (Sandoz) MabionCD20 (Mabion) BI (BI) SB5 (Samsung) Biocon CHS-1420 (Coherus) (BOW050) Epirus SB4 (Samsung Bioepis) BI GS071 (Aprogen) SB2 (Samsung Bioepis) AP052 (Aprogen) ABP 798 (Amgen) GP2013 (Sandoz) PF (Pfizer) BioXpress Harvest Moon PF (Pfizer/Sandoz) CT-P10 (Celltrion) MK-8808 (Merck) Harvest Moon Infliximab Rituximab 15 Source: IMS Health, IMS Institute for Healthcare Informatics, Jan 2016 The Biologic / Biosimilar Challenges Branded medicine prescribing Question - Is this sustainable as the number of products increase exponentially? Issues prescriber knowledge stock holding in hospitals risk of unintended switching risk of medication errors 16 8
9 Contracting for Biosimilars in the UK Commercial Medicine Unit (CMU) in England (plus Scotland Ireland and Wales) The CMU /England model National specifications and processes ensures adherence to Public Procurement Law allows market management Generic and Branded contracts very different Branded processed in Tranches ie into subgroups where there is a potential for therapeutic competition Eg anti fungals / EPO / HIV drugs / Growth Hormone anti-tnfs Biosimilars -- - Branded into appropriate subgroups 17 Branded Contracting Not contracts but frameworks all products on the framework 2 year duration 4 supra regions North /South /Midlands /London staggered every 6 months with opportunity for a price review at 12 months Interim / transition agreements to allow new entrants to be included outwith the normal cycle to ensure no barrier to entry ONLY THE FIRST STEP --- then regional choice No product differentiation the driver is cost Evolutionary not written in Tablets of Stone 18 9
10 True product differentiation Ready to use products Extended shelf life of reconstituted products Different logistics models eg Homecare Different devices Patient apps to improve compliance and reduce waste Non promotional education and training 19 The funding paradigm in the NHS - whose budget is it? High costs drugs budgets held by commissioners Bills are sent to them for payment (pass through) Provider Trusts need to negotiate a share of the savings A very mixed economy of invest to share A direct comparison to the mixed uptake 20 10
11 Jan 14 Mar 14 May 14 Jul 14 Sep 14 Dec 14 Feb 15 Apr 15 Jun 15 Aug 15 Oct 15 Dec 15 0% 10% 20% 30% 40% 50% 60% 70% 80% 90% 100% 29/04/2016 The UK uptake of infliximab is limited and concentrated Nationally, 23% of infliximab usage is biosimilar, with only 24 trusts using 50% or more of the biosimilar Infliximab use Trusts use of biosimilar 100% 90% 80% 70% 60% 50% 40% 30% 20% 10% 0% trusts 24 trusts REMICADE BIOSIMILAR % biosimilar versus originator infliximab usage Source: IMS Health. HPA, Oct-Dec 15 NAPP Indicators and measurement The national biosimilars group has agreed three indicators These will work together to help track how the introduction of biosimilar medicines is driving better value for the NHS and treatment option choices for patients through increased competition Collection method required Medium term ambition Already in use An indexed measure of enhanced value captured by Trusts in HoPMOP through the increased competition A measure of impact on the overall patient access to biologic treatment through the introduction of competition A tracking of the use of biosimilars by Trust with which to gauge the pattern of competition 11
12 Conclusions Clinician and patient buy in essential Opportunities for Champions and early adopters sharing good practice and ongoing education / peer review required Working effectively with biologics / biosimilars companies to mitigate barriers to introduction Contracting for medicines needs to be flexible to support competition and entry of new players and reflect the changing market Invest to save opportunities to Provider Trusts managing the change remove the funding barrier Robust data including patient outcomes data required to support the biosimilars agenda 23 12
Biosimilars contracting in the NHS. Maggie Dolan Regional Pharmacy Procurement Specialist South East Coast
Biosimilars contracting in the NHS Maggie Dolan Regional Pharmacy Procurement Specialist South East Coast Aim Introduction Managing the Medicine Budget in the NHS The Biosimilar Medicine Challenges Questions
More informationWhat next? Manufacture the biosimilar product
What next? Manufacture the biosimilar product Design manufacturing process to match QTPP Full quality dossier required. Use state of the art technologies In accordance with relevant ICH and CHMP guidelines
More informationNHS BioValue: The Potential for a Landmark UK NHS Real World Evidence Study on Biosimilars
NHS BioValue: The Potential for a Landmark UK NHS Real World Evidence Study on Biosimilars Angela McFarlane Market Development Director, QuintilesIMS Angela.McFarlane@QuintilesIMS.com Copyright 2016 QuintilesIMS.
More informationCURRENT POLICY ON ACCESS TO MEDICINES AND HEALTH IN EUROPE. The role of Biosimilar Medicines
CURRENT POLICY ON ACCESS TO MEDICINES AND HEALTH IN EUROPE The role of Biosimilar Medicines Marc A. Mahl, MD MBA(INSEAD) President, Medicines for Europe Baltimore, 05 th September 2018 patients quality
More informationRegional Medicines Optimisation Committee Briefing Best Value Biologicals: Adalimumab Update 2
Regional Medicines Optimisation Committee Briefing Best Value Biologicals: Adalimumab Update 2 Adalimumab RMOC Update 1: https://www.sps.nhs.uk/articles/rmoc-briefing-paper-on-adalimumab/ The purpose of
More informationDelivering on the Potential of Biosimilar Medicines
March 2016 Delivering on the Potential of Biosimilar Medicines The Role of Functioning Competitive Markets Introduction As biologic medicines play a more significant role in patient care across a growing
More informationMedicines optimisation & the model hospital
Medicines optimisation & the model hospital - Securing value from medicines Andrew Davies, Professional Lead for Hospital Pharmacy, NHS Improvement Andrew.davies@nhs.net @HospChiefPharm Commissioning Chemotherapy
More informationThe introduction of biosimilars into clinical practice
Commissioning Chemotherapy Services The introduction of biosimilars into clinical practice Jatinder Harchowal Chief Pharmacist / Clinical Director Royal Marsden NHS Foundation Trust Medicines lead for
More informationBiosimilars 2016 Balancing Fast Uptake with Industry Sustainability. Dan Ionescu Head of Pricing and Market Access Sandoz Biopharmaceuticals
Biosimilars 2016 Balancing Fast Uptake with Industry Sustainability Dan Ionescu Head of Pricing and Market Access Sandoz Biopharmaceuticals 10 years on, biosimilars have had a strong impact on global healthcare
More informationBiosimilars Market Update
Biosimilars Market Update Panel: Matthew Brougham Consultant Economist, Brougham Consulting Inc Mark Jackson Consultant Pharmacist, TELUS Health Dr. Ed Keystone Professor of Medicine, University of Toronto
More informationTrends in Medication Management. Jayson Gallant, B.Pharm, M.Sc Pharmacist, Health Benefit Management
Trends in Medication Management Jayson Gallant, B.Pharm, M.Sc Pharmacist, Health Benefit Management Agenda Drug Claims Trends Legislative / Public Plan Initiatives Biosimilars Pipeline Focus on Oncology
More informationPharmacovigilance in Oncology. Luis H. Camacho, MD, MPH Houston, USA
Pharmacovigilance in Oncology Luis H. Camacho, MD, MPH Houston, USA 5th European Biosimilar Congress - Valencia June 27-29, 2016 Disclosure Director, Center for Oncology and Blood Disorders. Secretary,
More informationEvolving U.S. Biosimilars Landscape
Evolving U.S. Biosimilars Landscape A Medical Affairs Perspective By Thao Sutter and Bryan Katz Syneos Health Consulting 2018 Syneos Health. All rights reserved. Introduction The U.S. biosimilar landscape
More informationas they ordinarily would for a generic. This has been a key factor inhibiting biosimilar uptake.
PEB OVR 6.1 Agenda Item 6 BIOSIMILARS REIMBURSEMENT 1 Purpose of Item 1.1 The Minister (delegate) requests the Pharmaceutical Benefits Advisory Committee (PBAC) provide advice on the following matter(s)
More informationNHS England, National QIPP Delivery Programme, Medicines Management & Optimisation
NHS England, National QIPP Delivery Programme, Medicines Management & Optimisation Biosimilars National Surveys; CCGs and NHS Trusts Summary Report - April 2018 1.0 Background This report summarises the
More informationBiosimilars - more for less
Biosimilars - more for less Per Troein VP Strategic Partners, IMS Health 0 Agenda The Global trend for Biologicals An European overview of present status of biosimilars What can be learnt form Infliximab
More informationTendering for Medicines and Services with CMU. Kevan Wind, Medicines Procurement Specialist Pharmacist, London & East of England
Tendering for Medicines and Services with CMU Kevan Wind, Medicines Procurement Specialist Pharmacist, London & East of England What we will cover 1. Pricing and Procurement of Medicines in the NHS. 2.
More informationBetter Access, Better Health A guide to the generic and biosimilars medicines market and pricing
Better Access, Better Health A guide to the generic and biosimilars medicines market and pricing Section 1: About the BGMA & Generics The British Generic Manufacturers Association (BGMA) is made up of
More informationHow to maximize patient access Perspectives from The Netherlands
Budapest, June 13, 2018 How to maximize patient access Perspectives from The Netherlands Vs18f13 Arnold G. Vulto PharmD PhD FCP Professor Em. of Hospital Pharmacy & Practical Therapeutics Erasmus University
More informationCoherus BioSciences 2018 CANTOR GLOBAL HEALTHCARE CONFERENCE OCTOBER 2, Copyright 2018 All Rights Reserved.
Coherus BioSciences 2018 CANTOR GLOBAL HEALTHCARE CONFERENCE OCTOBER 2, 2018 Copyright 2018 All Rights Reserved. Forward Looking Statements This presentation does not constitute or form any part of any
More informationThe value partnership between NHS, industry and other providers
The value partnership between NHS, industry and other providers Dr Richard Greville, Director Wales and Director Distribution & Supply, ABPI 12 April 2016 The Value Partnership between NHS, Industry and
More informationThe Impact of Patent Expiries on Future Drug Spending in Canada. CAHSPR Conference May 30, 2012
The Impact of Patent Expiries on Future Drug Spending in Canada CAHSPR Conference May 30, 2012 1 Outline Background Data Sources Methods Results Conclusion 2 Background Generics account for relatively
More informationThere are no secrets to success. It is the result of preparation, hard work, and learning from failure. Colin Powell
Welcome 1 2 There are no secrets to success. It is the result of preparation, hard work, and learning from failure. Colin Powell 5 FACTS about us 3 Established offers clinical Manufacturing sites Compliant
More informationHatch-Waxman: Driving Access, Savings & Innovation
Hatch-Waxman: Driving Access, Savings & Innovation Introduction Thirty years ago, Congress sought to create a balance between access to lower cost generic medicines and incentives to innovate new and better
More informationBiosimilar medicines: practical EU experience and perspectives. 12 Sept 2017 Adrian van den Hoven, Director General, Medicines for Europe
Biosimilar medicines: practical EU experience and perspectives 12 Sept 2017 Adrian van den Hoven, Director General, Medicines for Europe Medicines For Europe VISION Medicines for Europe Vision 2020 Our
More informationCoherus BioSciences. Jefferies 2016 Healthcare Conference. June 8, Copyright 2016 All Rights Reserved.
Coherus BioSciences Jefferies 2016 Healthcare Conference June 8, 2016 Copyright 2016 All Rights Reserved. Forward Looking Statements Except for the historical information contained herein, the matters
More informationAsia s Clout in Global Biosimilars
MIRAE ASSET LENS 4Q 2017 Mirae Asset Global Investments (Hong Kong) Asia Pacific Investment / Research Saniel Chandrawat, Senior Investment Analyst Sizing up the opportunity The global biosimilar market
More informationHow Biosimilars Track a Unique Sales Path:
How Biosimilars Track a Unique Sales Path: Three Case Studies to Help Anticipate Biosimilar Entry in Your Market Judith Kulich and Emily Jin How Biosimilars Track a Unique Sales Path: Three Case Studies
More informationRegulation of Biosimilars in Canada
Regulation of Biosimilars in Canada Session 2: Global Regulatory Trends of Biosimilars GBC 2018 June 28, 2018 Stephanie Hardy Office of Policy and International Collaboration Biologics and Genetic Therapies
More information+50% Market share for biosimilar G-CSF 2
The Biosimilar Market Leader s Perspective Carol Lynch, Global Head of Sandoz Biopharmaceuticals April 28, 2016 10 years on, biosimilars have had a strong impact on global healthcare Product Approvals
More informationGoldman Sachs Key Debates In Biosimilars Conference
Goldman Sachs Key Debates In Biosimilars Conference Diem Nguyen Regional President North America, Global Established Pharmaceuticals April 2, 2015 1 2 Forward Looking Statements Our discussions during
More informationPresenter. Guy Clark. Searle Pharmaceuticals Sales, Marketing, BD. Business Development Director, IVAX Europe. President, Glenmark Europe
Presenter Guy Clark Searle Pharmaceuticals Sales, Marketing, BD 1992-2001 Business Development Director, IVAX Europe 2001-2005 President, Glenmark Europe 2005-2008 Business Development Consultant 2009-2010
More informationBIOSIMILAR AWARENESS INITIATIVE PROJECT MANAGEMENT PLAN
BIOSIMILAR AWARENESS INITIATIVE PROJECT MANAGEMENT PLAN Date: June 2016 This document and its attachments are UNCLASSIFIED PRINCE2 Project Initiation Documentation TABLE OF CONTENTS 1 PROJECT DEFINITION...
More informationAn update on development strategies of recently approved biosimilars in Europe. Johanna Mielke
An update on development strategies of recently approved biosimilars in Europe Johanna Mielke Acknowledgement & disclaimer This project was supported by the Swiss State Secretariat for Education, Research
More informationGlobal Biosimilar Market Trends & Opportunities: 2015 Edition
Global Biosimilar Market Trends & Opportunities: 2015 Edition Global Biosimilar Market Trends & Opportunities: 2015 Edition BioPortfolio has been marketing business and market research reports from selected
More informationAdvancing Biosimilar Sustainability in Europe
SEPTEMBER 2018 Advancing Biosimilar Sustainability in Europe A Multi-Stakeholder Assessment Introduction A growing number of biologic medicines have been developed and approved over the past decade, improving
More informationManaging the introduction of new generic medicines: Guidance for Chief Pharmacists and Trust medicines procurement leads.
Introduction Managing the introduction of new generic medicines: Guidance for Chief Pharmacists and Trust medicines procurement leads. The loss of exclusivity and launches of new generic medicines allows
More informationManaging the introduction of new generic medicines: Guidance for Chief Pharmacists and Trust medicines procurement leads.
Introduction Managing the introduction of new generic medicines: Guidance for Chief Pharmacists and Trust medicines procurement leads. The loss of exclusivity and launches of new generic medicines allows
More informationProfessor Ahmed H Al-jedai, PharmD, MBA, BCPS, FCCP, FAST, Saudi Arabia
GaBI Scientific Meetings First GCC Stakeholder Meeting on Approval Process, Interchangeability/Substitution and Safety of Biosimilars 20 November 2017, Holiday Inn Izdihar Riyadh, Saudi Arabia Professor
More informationSustainable Competition:
Sustainable Competition: the Magic Formula to Align Public Health and Business Objectives for Access Adrian van den Hoven Director General Medicines for Europe Medicines For Europe VISION Medicines for
More informationBiomanufacturing Capacity for Biosimilars: Is there enough?
Biomanufacturing Capacity for Biosimilars: Is there enough? Cambridge Healthtech Institute s Third Annual BIOAnalytical Summit 2012 Mar 19-22 Baltimore, MD BioProcess Technology Consultants www.bptc.com
More informationBIOTECHNOLOGY IN EUROPE: KEY TRENDS
BIOTECHNOLOGY IN EUROPE: KEY TRENDS Eva Edery, Senior Principal, IMS Health Global Pharma Strategy EGA Symposium on Biosimilars, London, May 27 Agenda Global pharmaceutical trends Biotech market dynamics
More informationNHS England Regional Medicines Optimisation Committee (North) Summary Notes and Actions
NHS England Regional Medicines Optimisation Committee (North) Summary Notes and Actions Wednesday 28 th February 2018, 1-4pm, Webinar. Chair: Dr Mike Prentice (Medical Director, NHSE North Region) Attendees:
More informationOptimising medicines use, value and funding
Optimising medicines use, value and funding Dr Keith Ridge, Chief Pharmaceutical Officer December 2017 Medicines Achieving are the an NHS important Five Year part of NHS care and Forward help many View
More informationBiologicals & biosimilars; addressing the needs of patients and payers. The Role of Functioning Competitive Markets
Biologicals & biosimilars; addressing the needs of patients and payers The Role of Functioning Competitive Markets Agenda Why do patients and payers need biosimilars? How can we increase the uptake of
More informationAre Biosimilars the Panacea for High Cost Specialty Drugs?
Are Biosimilars the Panacea for High Cost Specialty Drugs? Mid-sized Retirement and Healthcare Plan Management San Francisco, CA March 27, 2018 2018. Innovative Rx Strategies, LLC. All rights reserved.
More informationGlobal Oncology Biosimilars Market
Published on Market Research Reports Inc. (https://www.marketresearchreports.com) Home > Global Oncology Biosimilars Market 2016-2020 Global Oncology Biosimilars Market 2016-2020 Publication ID: TNV0216071
More informationBiosimilar medicines rising to the cost challenge
Chapter 3 Biosimilar medicines rising to the cost challenge Addressing the rising cost of biological medicines has become a priority for governments and healthcare systems around the globe. Biosimilar
More informationBIOSIMILARS OF PROTEIN BASED DRUGS: CURRENT STATUS AND FUTURE DIRECTIONS
BIOSIMILARS OF PROTEIN BASED DRUGS: CURRENT STATUS AND FUTURE DIRECTIONS George Dranitsaris B.Pharm. PhD Consultant in Health Economics and Biostatistics What is a Biosimilar? Protein based drugs are made
More informationCancer Vanguard. Biosimilars Trust Policy Template
Cancer Vanguard Biosimilars Trust Policy Template Aim of this document: The document provides generic guidance and outline for the development of local trust policies in relation to the adoption of biosimilars
More informationCoherus BioSciences. Jefferies 2016 London Healthcare Conference. November 16, Copyright 2016 All Rights Reserved.
Coherus BioSciences Jefferies 2016 London Healthcare Conference November 16, 2016 Copyright 2016 All Rights Reserved. Forward Looking Statements Except for the historical information contained herein,
More informationPharmaceutical Law & Industry Report
Pharmaceutical Law & Industry Report Reproduced with permission from Pharmaceutical Law & Industry Report, 16 PLIR 199, 02/09/2018. Copyright 2018 by The Bureau of National Affairs, Inc. (800-372-1033)
More informationClinical Evaluation and Interchangeability of Biotech Products and Biosimilars (a Clinical Pharmacists View)
Athens, May 25, 2018 Clinical Evaluation and Interchangeability of Biotech Products and Biosimilars (a Clinical Pharmacists View) Vs18e28 Arnold G. Vulto PharmD PhD FCP Professor of Hospital Pharmacy &
More informationGlobal Demand and Utilization of Mammalian Cell Culture Manufacturing Capacity
Global Demand and Utilization of Mammalian Cell Culture Manufacturing Capacity Howard L. Levine, Ph.D. Eighth Annual BioProcess International Europe 2012 Apr 18-19 Prague, Czech Republic BioProcess Technology
More informationBiosimilars Update 4/23/2015. The Biosimilar Roadmap From concept to delivery. Conflict of Interest Disclosure. Collaborate Cultivate Educate
Collaborate Cultivate Educate Biosimilars Update Conflict of Interest Disclosure We have no actual or potential conflict of interest in relation to this program and presentation. Brad Patten Patrick Leary
More informationThe. Altascientist SEPTEMBER 2018 ISSUE NO. 4
The Altascientist SEPTEMBER 2018 ISSUE NO. 4 Altasciences has the perfect mix of innovator and generic drug development experience, with a thorough understanding of the regulatory complexities involved
More informationFebruary September 11, See, for example, Guidance for Industry on Biosimilars: Q & As Regarding Implementation of the BPCI Act of 2009:
February 2014 Biosimilars: Strategic considerations for interchangeability The future timing, magnitude, and impact of the anticipated biosimilar wave continue to be in flux. Major biopharmaceutical manufacturers
More informationUBCM Conference. Joanne Jung, BScPharm Director, Pharmacy Services Mar 10, 2016
UBCM Conference Joanne Jung, BScPharm Director, Pharmacy Services Mar 10, 2016 Agenda Drug Landscape Private drug plan trends Cost drivers Specialty Drugs Drug Trends Top Therapeutic Classes Drug Plan
More informationFACTORS SUPPORTING A SUSTAINABLE EUROPEAN BIOSIMILAR MEDICINES MARKET
FACTORS SUPPORTING A SUSTAINABLE EUROPEAN BIOSIMILAR MEDICINES MARKET A study undertaken by GfK Market Access on behalf of the European Biosimilars Group, a sector group of EGA, about the future sustainability
More informationBRITISH GENERIC MANUFACTURERS ASSOCIATION
BRITISH GENERIC MANUFACTURERS ASSOCIATION Response by the British Generic Manufacturers Association (BGMA) to the Department of Health Consultation on Amendments to the Statutory Scheme to Control the
More informationBiosimilar medicines rising to the cost challenge
Chapter 3 Biosimilar medicines rising to the cost challenge Addressing the rising cost of biological medicines has become a priority for governments and healthcare systems around the globe. Biosimilar
More informationHFMA Brighter Together - Procurement Forum The Future of NHS Procurement. Howard Blackith, Chief Information Officer
HFMA Brighter Together - Procurement Forum The Future of NHS Procurement Howard Blackith, Chief Information Officer Agenda Background Current Procurement Landscape Programme Update The Change Our Programme
More informationBiosimilars in Clinical Practice: Formulary, interchange and substitution considerations (a European perspective)
Soul, September 14, 2017 Biosimilars in Clinical Practice: Formulary, interchange and substitution considerations (a European perspective) Vs17i13 Arnold G. Vulto PharmD PhD FCP Professor of Hospital Pharmacy
More informationGlobal biosimilar policy comparison. Overview of biosimilar policies across 9 major markets in the battle to control healthcare sustainability
Global biosimilar policy comparison Overview of biosimilar policies across 9 major markets in the battle to control healthcare sustainability Table of contents I. Introduction... 3 1. Goal... 3 2. Research
More informationWorkshop on Access to and Uptake of Biosimilar Medicinal Products
EUROPEAN COMMISSION Directorate-General for Internal Market, Industry, Entrepreneurship and SMEs Consumer, Environmental and Health Technologies Biotechnology and Food Supply Chain Workshop on Access to
More informationMARCH Express Scripts 2015 Drug Trend Report Executive Summary
MARCH 2016 Express Scripts 2015 Drug Trend Report Executive Summary Together we brought down out-of-pocket costs for patients and slowed the increase in U.S. drug spend. G oing into 2015, healthcare payers
More informationThe generics environment today
The generics environment today Sergio Napolitano EGA Director Legal Affairs and Trade 2 October 2015, Warsaw C O M PA N I E S N AT I O N A L A S S O C I AT I O N S EGA Membership GE (Hungary) SPMA (Slovenia)
More informationFactors Supporting a Sustainable European Biosimilar Medicines Market PROJECT SUMMARY FOR EXTERNAL COMMUNICATION
Market Access Factors Supporting a Sustainable European Biosimilar Medicines Market PROJECT SUMMARY FOR EXTERNAL COMMUNICATION A study undertaken by GfK Market Access on behalf of the European Biosimilars
More informationBGMA Associate Membership
BGMA Associate Membership Making medicines affordable Promoting Innovation November 2011 GENERICS -THE FACTS Generic medicines meet the same standards of quality, safety and efficacy as originator brands.
More informationStructural Market Changes Needed in U.S. to Achieve Cost-Savings from Biosimilars
Structural Market Changes Needed in U.S. to Achieve Cost-Savings from Biosimilars Lessons from Europe s Biosimilars Successes: Payer, Physician, and Patient Alignment Will Lower Costs, Increase Access
More informationREFERENCE CODE GDHC1113CFR PUBLICATION DATE M AY 2013
REFERENCE CODE GDHC1113CFR PUBLICATION DATE M AY 2013 PSORIASIS - Executive Summary Sales for Psoriasis in China 2012 2022 We estimate the 2012 PsO drug sales to be $392.2m in China. By forecast end in
More information: Regulation of biosimilars and success factors for uptake in clinical practice. Steinar Madsen, MD, FACP(Hon) Medical director
2018-02-08: Regulation of biosimilars and success factors for uptake in clinical practice Steinar Madsen, MD, FACP(Hon) Medical director steinar.madsen@legemiddelverket.no Drug costs in Norway Billion
More informationACG Public Forum. Join ACG, the FDA, and EMA for a discussion on biosimilars and IBD. Monday, 12:45 pm 2:15 pm
ACG Public Forum Join ACG, the FDA, and EMA for a discussion on biosimilars and IBD Monday, 12:45 pm 2:15 pm ACG 2017: FDA-EMA workshop on biosimilars Joachim Musaus EMA Product Lead Gastroenterology Human
More informationA Physician s consideration towards Biosimilars. João Eurico Fonseca
A Physician s consideration towards Biosimilars João Eurico Fonseca Disclosure I received unrestricted research grants or acted as a speaker for Abbvie, Amgen, BMS, Celtrion, Celgene, Janssen, MSD, Novartis,
More informationHealthcare (Overweight/Maintain)
(Overweight/Maintain) FDA approval of Zarxio opens doors to US biosimilar market News Comment US FDA approves Sandoz s Zarxio, the first biosimilar to be sold in the US The FDA approval increases visibility
More informationThe Evolving Role Of Prescription Benefit Managers
The Evolving Role Of Prescription Benefit Managers Steve Miller, MD Senior Vice President & Chief Medical Officer November 1, 2016 1 Prescription drugs: A growing share of U.S. healthcare spend Net spending
More informationREFERENCE CODE GDHC1180DFR PUBLICATION DATE M AY 2013
REFERENCE CODE GDHC1180DFR PUBLICATION DATE M AY 2013 STELARA (PSORIASIS) - Executive Summary Table below presents key metrics for Stelara in the seven of the nine major pharmaceutical markets. Stelara:
More informationABPI 3 YEAR STRATEGIC PLAN
ABPI 3 YEAR STRATEGIC PLAN 2009 2010 2011 Introduction The ABPI s 3 year strategic plan lays out the Association s commitment to becoming world class: to surpass member s requirements; to lead the industry
More informationQuality Impact Assessment Procedure. July 2012
Quality Impact Assessment Procedure July 2012 1 Document name Quality Impact Assessment Procedure Version 3.0 Document author (name/title) Karen Warner Compliance lead (name/title) Mark Turner, Assurance
More informationFuture Trends in Biopharmaceutical Operations and Facilities
Presentation ISPE-Workshop on Single-Use Technologies in Biomanufacturing Processes 26-27 th May 2011, Marseilles, France Future Trends in Biopharmaceutical Operations and Facilities Johannes R. Roebers,
More informationREFERENCE CODE GDHC1106CFR PUBLICATION DATE M AY 2013
REFERENCE CODE GDHC1106CFR PUBLICATION DATE M AY 2013 PSORIASIS - Psoriasis - US Drug Forecast and Market Analysis to Executive Summary Sales for Psoriasis in the US 2012 We estimate the 2012 PsO drug
More informationInternal Business Case Template & Guidance
Internal Business Case Template & Guidance Creation of Chief Pharmacist Information Officer role at UHBristol 1. INTRODUCTION AND SUMMARY This document defines the need, strategic context and preferred
More information5th Annual National Association of Specialty Pharmacy Annual Meeting and Educational Conference
5th Annual National Association of Specialty Pharmacy Annual Meeting and Educational Conference September 18-20, 2017 Washington, DC Biosimilars: Price, Policy & Outlook Ron Lanton III, Esq. President
More informationNHS Procurement Transformation Programme Future Operating Model (FOM)
NHS Procurement Transformation Programme Future Operating Model (FOM) Overview July 2017 More info: FOM@dh.gsi.gov.uk 1 THE BIG PICTURE Headline Item in Press NHS has the potential, through greater collaboration,
More informationLondon Medicines Evaluation Network Review
London Medicines Evaluation Network Review Answers to commonly asked questions about biosimilar versions of infliximab February 2015 (revised April 2015) Authored by Nicola Hooker (Nicola.Hooker@gstt.nhs.uk)
More informationImplementation of Biosimilars: The Good, the Bad, the Ugly September 13, Learning Objectives. Audience Response 9/3/2018
Implementation of Biosimilars: The Good, the Bad, the Ugly September 13, 2018 Monica Macik, PharmD, BCPS, BCOP Clinical Pharmacy Specialist Hematology/Oncology Eskenazi Health Indianapolis, IN Karen Smethers,
More informationCoherus BioSciences. 37th Annual J.P. Morgan Global Healthcare Conference January 8, Copyright 2019 All Rights Reserved.
Coherus BioSciences 37th Annual J.P. Morgan Global Healthcare Conference January 8, 2019 Copyright 2019 All Rights Reserved. Forward Looking Statements This presentation does not constitute or form any
More informationCelltrion ( KQ)
Celltrion (068270 KQ) Buy (Initiate) Target Price (12M, W) 36,000 Share Price (09/03/12, W) 29,650 Expected Return (%) 21.4 EPS Growth (12F, %) 2.7 Market EPS Growth (12F, %) 12.7 P/E (12F, x) 29.9 Market
More informationConsiderations and reflections concerning implementation of biosimilar MABs in the clinic - focus on trastuzumab
Considerations and reflections concerning implementation of biosimilar MABs in the clinic - focus on trastuzumab Head of Department of Clinical Pharmacology, Bispebjerg and Frederiksberg Hospital PhD MD
More informationUKMI CONTRIBUTIONS TO THE MEDICATION SAFETY AGENDA. Ben Rehman Director, London Medicines Information Service
UKMI CONTRIBUTIONS TO THE MEDICATION SAFETY AGENDA Ben Rehman Director, London Medicines Information Service A broad portfolio Patient care Organisational and system safety Numerous Medicines Q&As Enquiry
More informationKingston Hospital NHS Foundation Trust Recovery Plan Update. Trust Board Meeting 29 th July 2015
Kingston Hospital NHS Foundation Trust Recovery Plan Update Trust Board Meeting 29 th July 2015 Summary We have been through a robust process to set the plan and have subsequently focused on further actions
More informationBiosimilars: Myth or Fact?
Objectives Biosimilars: Myth or Fact? RT Whiteman, PharmD Pharmacy Practice Resident St. Luke s Boise Medical Center By the end of the presentation, the audience will be able to: Explain the differences
More informationEU health policy. Strategy for the pharmaceutical industry and biosimilars. Salvatore D'Acunto. DG Research. DG Internal Market. DG Health & Consumers
Strategy for the pharmaceutical industry and biosimilars Salvatore D'Acunto European Commission Enterprise and Industry Directorate-General London, 3 April 2014 EU health policy DG Research R&D, innovation
More informationBoard of Directors Meeting Report 5 September Agenda item 70/17
Board of Directors Meeting Report 5 September 2017 Agenda item 70/17 Title Sponsoring Director Author(s) Procurement Transformation Plan James O Sullivan Tracey Leforte Purpose To seek board approval Executive
More informationThe Payor s Perspective: Regulating to incentivise value creation and repair a failed market
CLINICAL INNOVATION: Fair & Effective Incentives for New Uses of Established Drugs The Payor s Perspective: Regulating to incentivise value creation and repair a failed market Moderator: Nancy E. Taylor
More informationNHS Supply Chain May SME participation figure is 28% by sales value across both transacted and nontransacted
SME Engagement and Participation The SME Special Interest Group has deemed that it is more fair and equitable, and in line with OJEU compliance, that NHS Supply Chain put processes and allied measures
More informationa) Seek clarification from the Department for Transport in respect of future core funding for the work of the Strategic Transport Forum.
Strategic Transport Forum 15 th December 2017 englandseconomicheartland@b uckscc.gov.uk Agenda Item 6: Draft Business Plan Recommendation: It is recommended that the Forum: a) Seek clarification from the
More informationBiosimilars 101: How similar are they?
Biosimilars 101: How similar are they? Matthew Marston, Pharm.D., BCPS, BCOP Senior Manager of Clinical Pharmacy Services Miller Drug, LLC Outline Describe the approval and manufacturing process of biologics
More informationProfessor Kimme Hyrich, MD, PhD, FRCPC, UK
GaBI Scientific Meetings 26 January 2017, Pullman London St Pancras, London, UK ROUNDTABLE ON REGISTRIES Practical Considerations for Registries making them work Professor Kimme Hyrich, MD, PhD, FRCPC,
More informationBUY BIOCON. Regulatory bump in EU; potential delay ahead. Target Price: Rs 380. Valuation
Regulatory bump in EU; potential delay ahead EMA s Committee for Medicinal Products for Human use (CHMP) has asked Biocon to withdraw its Peg-filgrastim and Trastuzumab filings in EU post the recent inspections
More information